Adrenomyeloneuropathy (AMN) is a late-onset axonopathy of spinal cord tracts caused by mutations of the ABCD1 gene that encodes adrenoleukodystrophy protein (ALDP), a peroxisomal transporter of very long-chain fatty acids (VLCFA). Disturbed metabolic interaction between oligodendrocytes (OL) and axons is suspected to play a major role in AMN axonopathy. To develop a vector targeting OL, the human ABCD1 gene driven by a short 0.3 kb part of the human myelin-associated glycoprotein (MAG) promoter was packaged into an adeno-associated viral serotype 9 (rAAV9). An intravenous injection of this vector on postnatal day 10 in Abcd1−/− mice, a model of AMN, allowed a near normal motor performance to persist for 24 months, while age-matched untreated mice developed major defects of balance and motricity. Three weeks postvector, 50–54% of spinal cord white matter OL was expressing human ALDP (hALDP) at the cervical level, and only 6–7% after 24 months. In addition, 29–32% of cervical spinal cord astrocytes at 3 weeks and 16–19% at 24 months also expressed ALDP. C26:0-lysoPC, a sensitive VLCFA marker of AMN, was lower by 41% and 50%, respectively, in the spinal cord and brain of vector-treated compared with untreated mice. In a nonhuman primate, the intrathecal injection of the rAAV9-MAG vector induced abundant ALDP expression at 3 weeks in spinal cord OL (43%, 29%, and 26% at cervical, thoracic, and lumbar levels) and cerebellum OL (35%). In addition, 33–41% of spinal cord astrocytes expressed hALDP, and 27% of cerebellar astrocytes. To our knowledge, OL targeting had not been obtained before in primates with other vectors or promoters. The current results thus provide a robust proof-of-concept not only for the gene therapy of AMN but also for other central nervous system diseases, where the targeting of OL with the rAAV9-MAG vector may be of interest.
Get full access to this article
View all access options for this article.
References
1.
MosserJ, DouarAM, SardeCO, et al.Putative X-linked adrenoleukodystrophy gene shares unexpected homology with ABC transporters. Nature, 1993; 361:726–730.
2.
MosserJ, LutzY, StoeckelME, et al.The gene responsible for adrenoleukodystrophy encodes a peroxisomal membrane protein. Hum Mol Genet, 1994; 3:265–271.
WiensK, BerrySA, ChoiH, et al.A report on state-wide implementation of newborn screening for X-linked Adrenoleukodystrophy. Am J Med Genet, 2019; 179:1205–1213.
5.
WiesingerC, EichlerFS, BergerJ. The genetic landscape of X-linked adrenoleukodystrophy, inheritance, mutations, modifier genes, and diagnosis. Appl Clin Genet, 2015; 8:109–121.
EngelenM, KempS, de VisserM, et al.X-linked adrenoleukodystrophy (X-ALD): clinical presentation and guidelines for diagnosis, follow-up and management. Orphanet J Rare Dis, 2012; 7:51.
8.
HuffnagelIC, van BallegoijWJC, van GeelBM, et al.Progression of myelopathy in males with adrenoleukodystrophy: towards clinical trial readiness. Brain, 2019; 142:334–343.
9.
PowersJM, DeCieroDP, ItoM, et al.Adrenomyeloneuropathy: a neuropathologic review featuring its noninflammatory myelopathy. J Neuropathol and Exp Neurol, 2000; 59:89–102.
10.
ChenYC, LeeYC, TsaiYS, et al.Unmasking adrenoleukodystrophy in a cohort of cerebellar ataxia. PLoS One, 2017; 12:e0177296.
11.
EngelenM, BarbierM, DijkstraIM, et al.X-linked adrenoleukodystrophy in women: a cross-sectional cohort study. Brain, 2014; 137:693–706.
12.
de BeerM, EngelenM, van GeelBM. Frequent occurrence of cerebral demyelination in adrenomyeloneuropathy. Neurology, 2014; 83:2227–2231.
13.
AubourgP, BlancheS, JambaquéI, et al.Reversal of early neurologic and neuroradiologic manifestations of X-linked adrenoleukodystrophy by bone marrow transplantation. N Engl J Med, 1990; 322:1860–1866.
14.
RaymondGV, AubourgP, PakerA, et al.Survival and functional outcomes in boys with cerebral adrenoleukodystrophy with and without hematopoietic stem cell transplantation. Biol Blood Marrow Transplant, 2019; 25:538–548.
15.
CartierN, Hacein-Bey-AbinaS, BartholomaeCC, et al.Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science, 2009; 326:818–823.
16.
EichlerF, DuncanC, MusolinoPL, et al.Hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy. N Engl J Med, 2017; 377:1630–1638.
17.
AsheuerM, PflumioF, BenhamidaS, et al.Human CD34+ cells differentiate into microglia and express recombinant therapeutic protein. Proc Natl Acad Sci USA, 2004; 101:3557–3562.
18.
BougnèresP, Hacein-Bey-AbinaS, LabikI, et al.Long-term follow-up of hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy. Human Gene Ther, 2021; 32:1260–1269.
19.
van GeelBM, Poll-TheBT, VerripsA, et al.Hematopoietic cell transplantation does not prevent myelopathy in X-linked adrenoleukodystrophy: a retrospective study. J Inherit Metab Dis, 2015; 38:359–361.
20.
PujolA, HindelangC, CallizotN, et al.Late onset neurological phenotype of the X-ALD gene inactivation in mice: a mouse model for adrenomyeloneuropathy. Hum Mol Genet, 2002; 11:499–505.
21.
GongY, MuD, PrabhakarS, et al.Adenoassociated virus serotype 9-mediated gene therapy for x-linked adrenoleukodystrophy. Mol Ther, 2015; 23:824–834.
22.
Gong YIMD, RenJ, MoserA, et al.Impact of rAAV9-ABCD1 upon behavioral outcome in a mouse model of X-ALD. Neurolog Dis, 2015; 23:S155.
23.
GongY, BerensonA, LahejiF, et al.Intrathecal adeno-associated viral vector-mediated gene delivery for adrenomyeloneuropathy. Human Gene Ther, 2019; 30:544–555.
24.
FrancisJS, MarkovV, WojtasID, et al.Preclinical biodistribution, tropism, and efficacy of oligotropic AAV/Olig001 in a mouse model of congenital white matter disease. Mol Ther Methods Clin Dev, 2021; 20:520–534.
25.
EykensC, RossaertE, DuquéS, et al.AAV9-mediated gene delivery of MCT1 to oligodendrocytes does not provide a therapeutic benefit in a mouse model of ALS. Mol Ther Methods Clin Dev, 2021; 20:508–519.
26.
NaveKA. Myelination and the trophic support of long axons. Nat Rev Neurosci, 2010; 11:275–283.
27.
FrühbeisC, Kuo-ElsnerWP, MüllerC, et al.Oligodendrocytes support axonal transport and maintenance via exosome secretion. PLoS Biol, 2020; 18:e3000621.
KassmannCM. Myelin peroxisomes—essential organelles for the maintenance of white matter in the nervous system. Biochimie, 2014; 98:111–118.
30.
StassartRM, MöbiusW, NaveKA, et al.The Axon-Myelin unit in development and degenerative disease. Front Neurosci, 2018; 12:467.
31.
BaarineM, AndréolettiP, AthiasA, et al.Evidence of oxidative stress in very long chain fatty acid—treated oligodendrocytes and potentialization of ROS production using RNA interference-directed knockdown of ABCD1 and ACOX1 peroxisomal proteins. Neuroscience, 2012; 213:1–18.
32.
StrachanLR, StevensonTJ, FreshnerB, et al.A zebrafish model of X-linked adrenoleukodystrophy recapitulates key disease features and demonstrates a developmental requirement for abcd1 in oligodendrocyte patterning and myelination. Hum Mol Genet, 2017; 26:3600–3614.
33.
von JonquieresG, FröhlichD, KlugmannCB, et al.Recombinant human myelin-associated glycoprotein promoter drives selective AAV-mediated transgene expression in oligodendrocytes. Front Mol Neurosci, 2016; 9:13.
34.
KojicM, GaikM, KiskaB, et al.Elongator mutation in mice induces neurodegeneration and ataxia-like behavior. Nat Commun, 2018; 9:3195.
35.
LuongTN, CarlisleHJ, SouthwellA, et al.Assessment of motor balance in mice using the balance beam. Jove, 2011; 23:2376–2378.
36.
TatsumiK, IsonishiA, YamasakiM, et al.Olig2-lineage astrocytes: a distinct subtype of astrocytes that differs from GFAP astrocytes. Front Neuroanat, 2018; 12:8.
37.
OhayonD, AguirrebengoaM, EscalasN, et al.Transcriptome profiling of the Olig2-expressing astrocyte subtype reveals their unique molecular signature. iScience, 2021; 7:1–25.
38.
WangH, XuL, LaiC, et al.Region-specific distribution of Olig2-expressing astrocytes in adult mouse brain and spinal cord. Mol Brain, 2021; 14:36–49.
39.
CahoyJD, EmeryB, KaushalA, et al.A transcriptome database for astrocytes, neurons, and oligodendrocytes: a new resource for understanding brain development and function. J Neurosci, 2008; 28:264–278.
40.
van de BeekMC, DijkstraIM, van LentheH, et al.C26:0-carnitine is a new biomarker for X-linked adrenoleukodystrophy in mice and man. PLoS One, 2016; 11:e0154597.
41.
SimonsM, NaveKA. Oligodendrocytes: myelination and axonal support. Cold Spring Harb Perspect Biol, 2015; 8:a020479.
42.
FoustKD, NurreE, MontgomeryCL, et al.Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol, 2009; 27:59–65.
43.
DuqueS, JoussemetB, RiviereC, et al.Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. Mol Ther, 2009; 17:1187–1196.
44.
GraySJ, MatagneV, BachaboinaL, et al.Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates. Mol Ther, 2011; 19:1058–1069.
45.
HudaF, KonnoA, MatsuzakiY, et al.Distinct transduction profiles in the CNS via three injection routes of AAV9 and the application to generation of a neurodegenerative mouse model. Mol Ther Methods Clin Dev, 2014; 1:14032.
46.
DashkoffJ, LernerEP, TruongN, et al.Tailored transgene expression to specific cell types in the central nervous system after peripheral injection with AAV9. Mol Ther Methods Clin Dev, 2016; 3:16081.
47.
BeyK, CironC, DubreilL, et al.Efficient CNS targeting in adult mice by intrathecal infusion of single-stranded AAV9-GFP for gene therapy of neurological disorders. Gene Ther, 2017; 24:325–332.
48.
BeyK, DeniaudJ, DubreilL, et al.Intra-CSF AAV9 and AAVrh10 administration in nonhuman primates: promising routes and vectors for which neurological diseases?. Mol Ther Methods Clin Dev, 2020; 17:771–784.
49.
BevanAK, DuqueS, FoustKD, et al.Systemic gene delivery in large species for targeting spinal cord, brain, and peripheral tissues for pediatric disorders. Mol Ther, 2011; 19:1971–1980.
50.
GraySJ, Nagabhushan KalburgiS, McCownTJ, et al.Global CNS gene delivery and evasion of anti-AAV-neutralizing antibodies by intrathecal AAV administration in non-human primates. Gene Ther, 2013; 20:450–459.
51.
SamaranchL, SalegioEA, San SebastianW, et al.Adeno-associated virus serotype 9 transduction in the central nervous system of nonhuman primates. Hum Gene Ther, 2012; 23:382–389.
52.
SamaranchL, SalegioEA, San SebastianW, et al.Strong cortical and spinal cord transduction after AAV7 and AAV9 delivery into the cerebrospinal fluid of nonhuman primates. Hum Gene Ther, 2013; 24:526–532.
53.
BucherT, DubreilL, ColleMA, et al.Intracisternal delivery of AAV9 results in oligodendrocyte and motor neuron transduction in the whole central nervous system of cats. Gene Ther, 2014; 21:522–528.
54.
HindererC, BellP, KatzN, et al.Evaluation of intrathecal routes of administration for adeno-associated viral vectors in large animals. Hum Gene Ther, 2018; 29:15–24.
55.
PowellSK, KhanN, ParkerCL, et al.Characterization of a novel adeno-associated viral vector with preferential oligodendrocyte tropism. Gene Ther, 2016; 23:807–814.
56.
PeelaertsW, BritoF, Van den HauteC, et al.Widespread, specific, and efficient transgene expression in oligodendrocytes after intracerebral and intracerebroventricular delivery of viral vectors in rodent brain. Hum Gene Ther, 2021; 2:616–627.
57.
BaileyRM, RozenbergA, GraySJ. Comparison of high-dose intracisterna magna and lumbar puncture intrathecal delivery of AAV9 in mice to treat neuropathies. Brain Res, 2020; 1739:146832.
58.
WangD, TaiPWL, GaoG. Adeno-associated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discov, 2019; 18:358–378.
59.
HocquemillerM, GierschL, AudrainM, et al.Adeno-associated virus-based gene therapy for CNS diseases. Hum Gene Ther, 2016; 27:478–496.
60.
GeorgiouE, SidiropoulouK, RichterJ, et al.Gene therapy targeting oligodendrocytes provides therapeutic benefit in a leukodystrophy model. Brain, 2017; 140:599–616.
61.
YoungKM, PsachaouliK, TripathiRB, et al.Oligodendrocyte dynamics in the healthy adult CNS: evidence for myelin remodeling. Neuron, 2013; 77:873–885.
62.
YeungMS, ZdunekS, BergmannO, et al.Dynamics of oligodendrocyte generation and myelination in the human brain. Cell, 2014; 159:766–774.
63.
ShimozawaN, TakashimaS, KawaiH, et al.Advanced diagnostic system and introduction of newborn screening of adrenoleukodystrophy and peroxisomal disorders in Japan. Int J Neonatal Screen, 2021; 7:3.
64.
KassmannCM, Lappe-SiefkeC, BaesM, et al.Axonal loss and neuroinflammation caused by peroxisome-deficient oligodendrocytes. Nat Genet, 2007; 39:969–976.
65.
DominguesHS, PortugalCC, SocodatoR, et al.Oligodendrocyte, astrocyte, and microglia crosstalk in myelin development, damage, and repair. Front Cell Dev Biol, 2016; 4:71.
66.
NaveKA, EhrenreichH. Time to revisit oligodendrocytes in multiple sclerosis. Nat Med, 2019; 25:364–366.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
